Based on the Keros Therapeutics Inc stock forecast from 10 analysts, the average analyst target price for Keros Therapeutics Inc is USD 30.58 over the next 12 months. Keros Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Keros Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Keros Therapeutics Inc’s stock price was USD 12.18. Keros Therapeutics Inc’s stock price has changed by +22.04% over the past week, +3.57% over the past month and -79.22% over the last year.
No recent analyst target price found for Keros Therapeutics Inc
No recent average analyst rating found for Keros Therapeutics Inc
Company Overview Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Read Less
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company'...Read More
Frequently Asked Questions About Keros Therapeutics Inc (KROS) Stock
Based on ratings from 10 analysts Keros Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 16 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on KROS's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for KROS is USD 30.58 over the next 12 months. The maximum analyst target price is USD 47 while the minimum anlayst target price is USD 15.
Unfortunately we do not have enough data on KROS's stock to indicate if its overvalued.
The last closing price of KROS's stock was USD 12.18.
The most recent market capitalization for KROS is USD 0.47B.
Based on targets from 10 analysts, the average taret price for KROS is projected at USD 30.58 over the next 12 months.
This means that KROS's stock price may go up by +151.09% over the next 12 months.
We can't find any ETFs which contains Keros Therapeutics Inc's stock.
As per our most recent records Keros Therapeutics Inc has 169 Employees.
Keros Therapeutics Inc's registered address is 1050 Waltham Street, Lexington, MA, United States, 02421.
You can get more information about it from Keros Therapeutics Inc's website at https://www.kerostx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Keros Therapeutics Inc (KROS) Stock
Based on ratings from 10 analysts Keros Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 16 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on KROS's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for KROS is USD 30.58 over the next 12 months. The maximum analyst target price is USD 47 while the minimum anlayst target price is USD 15.
Unfortunately we do not have enough data on KROS's stock to indicate if its overvalued.
The last closing price of KROS's stock was USD 12.18.
The most recent market capitalization for KROS is USD 0.47B.
Based on targets from 10 analysts, the average taret price for KROS is projected at USD 30.58 over the next 12 months.
This means that KROS's stock price may go up by +151.09% over the next 12 months.
We can't find any ETFs which contains Keros Therapeutics Inc's stock.
As per our most recent records Keros Therapeutics Inc has 169 Employees.
Keros Therapeutics Inc's registered address is 1050 Waltham Street, Lexington, MA, United States, 02421.
You can get more information about it from Keros Therapeutics Inc's website at https://www.kerostx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KROS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
